myradiologysolutions.bayer.com menu home about ussolutions.people.insights.congresseslocationsproductscomputed tomographyinjection systemsmedrad stellant ct injection systemwhat is power injection dose management & analyticsradimetrics enterprise platformcertegra p3t 2.0 certegra isi educationcontrastmagnetic resonancecontrastinjection systemsmedrad mrxperion mr injection systemmedrad spectris solaris ep mr injection systemmr accessoriesmedrad continuum mr infusion systemmedrad veris mr vital signs monitormedrad ecoilsmedrad certo mr wireless networkangiographyinjection systemsmedrad mark 7 arterion injection systemmedrad avanta fluid management injection systemmedrad mark v provis angiographic injection systemmolecular imagingmedrad intego pet infusion systemdose management & analyticsradimetrics enterprise platformcertegra p3t 2.0 certegra isieducationsyringes & disposablesservicevirtualcare directcare partnercare selectcare learning centerimage libraryvideo librarycontrast agentsradimetrics enterprise platformmedrad intego pet infusion systemmedrad stellant ct injection systemmedrad mark v provis angiographic injection systemmedrad mark 7 arterion injection systemdocuments & tools librarycomputed tomographymagnetic resonanceangiographymolecular imagingdose management & analyticsservicesyringes & disposables bayer group home page a global leader in diagnostic imaging solutions gadavist gadobutrol injection 1 mmol ml now approved for magnetic resonance angiography mra gadavist gadobutrol injection is nowapproved in the u.s. for mra to evaluateknown or suspected supra aortic or renalartery disease in adult and pediatricpatients including term neonates . indications and usage gadavist is indicated for use in magnetic resonance angiography mra to evaluate known or suspected supra aortic or renal artery disease in adult and pediatric patients including term neonates important safety information warning nephrogenic systemic fibrosis nsf gadolinium based contrast agents gbcas increase the risk for nsf among patients with impaired elimination of the drugs . avoid use of gbcas in these patients unless the diagnostic information is essential and not available with non contrasted mri or other modalities . nsf may result in fatal or debilitating fibrosis affecting the skin muscle and internal organs . the risk for nsf appears highest among patients with chronic severe kidney disease gfr 30 ml min 1.73 m2 or acute kidney injury screen patients for acute kidney injury and other conditions that may reduce renal function . for patients at risk for chronically reduced renal function for example age 60 years hypertension or diabetes estimate the glomerular filtration rate gfr through laboratory testing . for patients at highest risk for nsf do not exceed the recommended gadavist dose and allow a sufficient period of time for elimination of the drug from the body prior to any re administration . please see additional important safety information for gadavist bayer in radiology bayer in radiology leads with investment ininnovation from our roots in medrad injectors andcontrast research and development to state of the artequipment service and radiology informatics . we believe success comes from systems that are smarter by design powered by people committed to making a difference . choose from our range of imaging solutions below to learn more . imaging solutions powered by people.the logical choice for today and tomorrow . that s radiological computedtomography magneticresonance angiography molecularimaging dosemanagement & analytics service indications and important safety information indications and usage gadavist gadobutrol injection is a gadolinium based contrast agent indicated for use with magnetic resonance imaging mri to detect and visualize areas with disrupted blood brain barrier bbb and or abnormal vascularity of the central nervous system in adult and pediatric patients including term neonates to assess the presence and extent of malignant breast disease gadavist is indicated for use in magnetic resonance angiography mra to evaluate known or suspected supra aortic or renal artery disease in adult and pediatric patients including term neonates important safety information warning nephrogenic systemic fibrosis nsf gadolinium based contrast agents gbcas increase the risk for nsf among patients with impaired elimination of the drugs . avoid use of gbcas in these patients unless the diagnostic information is essential and not available with non contrasted mri or other modalities . nsf may result in fatal or debilitating fibrosis affecting the skin muscle and internal organs . the risk of nsf appears highest among patients with chronic severe kidney disease gfr 30 ml min 1.73 m2 or acute kidney injury screen patients for acute kidney injury and other conditions that may reduce renal function . for patients at risk for chronically reduced renal function for example age 60 years hypertension or diabetes estimate the glomerular filtration rate gfr through laboratory testing . for patients at highest risk for nsf do not exceed the recommended gadavist dose and allow a sufficient period of time for elimination of the drug from the body prior to any re administration . contraindication and important information about hypersensitivity reactions gadavist is contraindicated in patients with history of severe hypersensitivity reactions to gadavist . anaphylactic and other hypersensitivity reactions with cardiovascular respiratory or cutaneous manifestations ranging from mild to severe including death have uncommonly occurred following gadavist administration . before gadavist administration assess all patients for any history of a reaction to contrast media bronchial asthma and or allergic disorders . these patients may have an increased risk for a hypersensitivity reaction to gadavist . acute kidney injury in patients with chronic renal impairment acute kidney injury sometimes requiring dialysis has been observed with the use of some gbcas . do not exceed the recommended dose ; the risk of acute kidney injury may increase with higher than recommended doses . extravasation and injection site reactions ensure catheter and venous patency before the injection of gadavist . extravasation into tissues during gadavist administration may result in moderate irritation . overestimation of extent of malignant disease in mri of the breast gadavist mri of the breast overestimated the histologically confirmed extent of malignancy in the diseased breast in up to 50 % of the patients . low sensitivity for significant arterial stenosis the performance of gadavist mra for detecting arterial segments with significant stenosis 50 % renal 70 % supra aortic has not been shown to exceed 55 % . therefore a negative mra study alone should not be used to rule out significant stenosis . adverse reactions the most frequent 0.5 % adverse reactions associated with gadavist in clinical studies were headache 1.5 % nausea 1.1 % and dizziness 0.5 % . please see full prescribing information . back to top you are encouraged to report negative side effects or quality complaints of prescription drugs to the fda . visit www.fda.gov medwatch or call 1 800 fda 1088 . bayer the bayer cross certegra p3t medrad stellant xds veris spectris solaris spectris directcare partnercare virtualcare selectcare mark 7 arterion and mark v provis are registered trademarks of the bayer group of companies . radimetrics mrxperion avanta twist & go and vflow are trademarks of the bayer group of companies . 2016 bayer healthcare llc . all rights reserved . 100 bayer boulevard po box 915 whippany nj 07981 terms of use privacy policy site map contact us transparency in supply chains site last modified august 2016 you are about to leave the radiology solutions website by opening a new webpage . the site you are linking to is not controlled by bayer healthcare and we are not responsible for the content presented on that site . thank you for visiting radiologysolutions.bayer.com . would you like to leaveradiologysolutions.bayer.com ok cancel thank you please tap verify below to complete your registration for your free copy of mri made easy . verify send to a colleague if you would like to share this page with a colleague simply fill out the form below and an e mail with a link will be sent on your behalf . your information title dr mr mrs ms first name last name e mail address your colleague s information title dr mr mrs ms first name last name e mail address your e mail has been sent .